Photo from Ghassan Abou-Alfa/X
Aug 16, 2024, 14:08
Ghassan Abou-Alfa: MSK Cancer Center keeps pressing for new therapy for fibrolamellar carcinoma
Ghassan Abou-Alfa, Associate Attending at Memorial Sloan Kettering Cancer Center, shared on X:
“Memorial Sloan Kettering Cancer Center, MSK Department of Medicine keep pressing for new therapy for fibrolamellar carcinoma.
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without mTOR Inhibitors in Patients with Fibrolamellar Carcinoma.”
Additional information.
Source: Ghassan Abou-Alfa/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06